经皮冠状动脉介入术前应用不同剂量氢氯吡格雷的疗效与安全性分析

Efficacy and Safety of Different dose of Clopidogrel Before the Application of Percutaneous Coronary Intervention

目的探究在经皮冠状动脉介入手术前采用不同剂量的氢氯吡格雷治疗的治疗效果以及分析药物治疗安全性;方法方便选取2016年2—12月进入该院治疗并被确诊为需要经皮冠状动脉介入治疗的患者共230例,将患者随机分为低剂量组与高剂量组;比较两组患者在接受不同治疗后患者的血小板活化、血小板聚集率等指标的差异,并在治疗后1个月与6个月随访。结果高剂量组患者的CD63、CD62P、TSP等血小板活化指标均高于低剂量组,数据间的差异有统计学意义(P<0.05);治疗后高剂量患者的MA为(36.45±3.59)mm,血小板聚集率为(50.23±4.37)%,明显低于低剂量组,而血小板抑制率为(53.27±3.78)%,与对照组相比明显升高,数据间差异有统计学意义(P<0.05)。结论在PCI前采用450 mg氯吡格雷能显著提高患者血小板凝集,治疗后不良反应发生率低,值得在临床上推广。

Objective This paper tries to explore the therapeutic effect of different doses of clopidogrel in the treatment of percutaneous coronary intervention and to analyze the safety of drug therapy. Methods 230 cases underwent percutaneous coronary treatment in this hospital from Feburary 2016 to December 2016 were convenient selected and were randomly divided into low dose group and high dose group. The differences of platelet activation and platelet aggregation rate between the two groups were compared after 1 month and 6 months follow-up. Results The platelet activation indexes of CD63,CD62 P and TSP were higher in the high dose group than those in the low dose group（P〈0.05）. The high dose of MA was（36.45±3.59）mm and platelet aggregation rate was（50.23±4.37）%, significantly lower than those of the low dose group, and the platelet inhibition rate was（53.27±3.78）%, significantly increased, the difference between the data was significantly different（P〈0.05）. Conclusion The use of 450 mg clopidogrel before the PCI can significantly improve patients＇ platelet aggregation, the incidence of adverse reactions after treatment is low, with is worthy of clinical promotion.